<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096781</url>
  </required_header>
  <id_info>
    <org_study_id>50864</org_study_id>
    <nct_id>NCT04096781</nct_id>
  </id_info>
  <brief_title>Engaging Patients to Help Achieve Increased Patient Choice and Engagement for AFib Stroke Prevention</brief_title>
  <acronym>ENHANCE-AF</acronym>
  <official_title>Engaging Patients to Help Achieve Increased Patient Choice and Engagement for AFib Stroke Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>East Carolina University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, randomized controlled 2-arm trial comparing the effectiveness of an
      innovative shared decision-making pathway and usual care for Atrial Fibrillation Stroke
      Prevention
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Shared Decision-Making pathway focused on a digital shared decision-making tool (SDMT) that is augmented by a clinician tool and an optional lay coach</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decisional Conflict Scale</measure>
    <time_frame>Visit 2 (1-month follow-up)</time_frame>
    <description>The Decisional Conflict Scale is a 16 Item scale on whether the participants have enough information to make a clear decision. Each item scored from 1-5, where 1 indicates clarity and 5 indicates confusion, with total score ranging from 16-80</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decisional Conflict Scale (16 items)</measure>
    <time_frame>Baseline, 1-month follow up, 6-month follow-up</time_frame>
    <description>The Decisional Conflict Scale is a 16 Item scale on whether the participants have enough information to make a clear decision. Each item scored from 1-5, where 1 indicates clarity and 5 indicates confusion, with total score ranging from 16-80</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decision Regret Scale (5 items)</measure>
    <time_frame>Baseline, 1-month follow up, 6-month follow-up</time_frame>
    <description>Decision Regret Scale, is scored from 1-5, where 1 indicates they made the right decision and 5 indicates they made the wrong decision. This scale ranges from 5-25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-selected weighted composite outcome scale</measure>
    <time_frame>Baseline, 1-month follow up, 6-month follow-up</time_frame>
    <description>Patient-selected weighted composite outcome scale is a composite scale to consider both decisional conflict and decisional regret scales simultaneously according to the priority based on the survey of 100 potential participants. The rationale for this endpoint is to consider not only the preference of majority patients (73%) but also the minority (27%) participants who prefer the decisional regret scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preparation for Decision Making Scale (10 items)</measure>
    <time_frame>Baseline, 1-month follow up, 6-month follow-up</time_frame>
    <description>Preparation for Decision Making scale assesses a patient's perception of how useful a decision aid or other decision support intervention is in preparing the respondent to communicate with their practitioner at a consultation focused on making a health decision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utah-Stanford Atrial Fibrillation Knowledge Assessment</measure>
    <time_frame>Baseline, 1-month follow up, 6-month follow-up</time_frame>
    <description>Newly developed assessment for this study to record Atrial Fibrillation Knowledge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Communication (Based on CAHPS Clinician &amp; Group Survey)</measure>
    <time_frame>Baseline</time_frame>
    <description>CAHPS 3-item modified version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Fibrillation Severity Scale (AFSS)</measure>
    <time_frame>Baseline, 1-month follow up, 6-month follow-up</time_frame>
    <description>The University of Toronto Atrial Fibrillation Severity Scale (AFSS) is a questionnaire designed for patients with AFib. It consists of 19 items combined into 3 parts to capture total AF burden, health care utilization, and the severity of AFib related symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collaborative Agreement on Decision</measure>
    <time_frame>Baseline</time_frame>
    <description>Developed by the University of Utah to assess the Collaborative Agreement (1. Patient Reported Outcome 2) Clinician Reported 3) Electronic Health Record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician Satisfaction of the Decision Aid: Physician Survey</measure>
    <time_frame>Baseline</time_frame>
    <description>Clinician Satisfaction of the Decision Aid as assessed by a physician survey on shared decision making</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction of the Decision Aid: Patient Survey</measure>
    <time_frame>Baseline</time_frame>
    <description>Patient Satisfaction of the Decision Aid as assessed by Patient survey on shared decision making</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Visit at visit 1 (clinician)</measure>
    <time_frame>Baseline</time_frame>
    <description>Compare treatment arm on the length of visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulant Choice and Persistence (Patient follow up questions on Anticoagulant use)</measure>
    <time_frame>Baseline, 1-month follow up, 6-month follow-up</time_frame>
    <description>Decision on anticoagulation choice as assessed by patient follow up questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anticoagulation Persistence (Patient follow up questions on Anticoagulant use)</measure>
    <time_frame>1-month follow up, 6-month follow-up</time_frame>
    <description>Persistence to anticoagulation among participants selecting anticoagulation, as assessed by Patient follow up questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke or TIA or Deep Venous Thrombosis or Pulmonary Embolus</measure>
    <time_frame>1-month follow up, 6-month follow-up, Unscheduled</time_frame>
    <description>Incidence of Stroke or TIA or Deep Venous Thrombosis or Pulmonary Embolus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>1-month follow up, 6-month follow-up, Unscheduled</time_frame>
    <description>Incidence of Death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <condition>Stroke</condition>
  <condition>Cardiac</condition>
  <condition>Heart Failure</condition>
  <condition>Arrhythmia</condition>
  <arm_group>
    <arm_group_label>Shared Decision Making Tool (SDMT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>SDMT</intervention_name>
    <description>The intervention involves a clear pathway centered on the use of a web-based decision tool. This tool aims to support the shared decision-making process for anticoagulation for stroke prevention in atrial fibrillation. This web-based tool will be used both by the participants as well the physician responsible for atrial fibrillation decision making.</description>
    <arm_group_label>Shared Decision Making Tool (SDMT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>The participants will receive usual care.</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥ 18 y/o

          -  Non-valvular atrial fibrillation or atrial flutter (AFib)

          -  CHA2DS2-VASc stroke score of:

               -  Men: 2 or more

               -  Women: 3 or more

          -  Able to consent in English or Spanish (if resources allow) and follow study
             instructions

        Exclusion Criteria:

          -  Moderate to severe mitral stenosis

          -  Mechanical valve replacement

          -  Absolute contraindication to anticoagulation (Based on clinician judgment)

          -  Indication for anticoagulation therapy for a condition other than atrial fibrillation

          -  Left atrial appendage exclusion (by surgery or device placement)

          -  At the clinical discretion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul J Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Randall S Stafford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul J Wang, MD</last_name>
    <phone>(650) 723-9363</phone>
    <email>pjwang@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie DeSutter</last_name>
      <phone>650-725-4151</phone>
      <email>ksutter@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>May 3, 2020</last_update_submitted>
  <last_update_submitted_qc>May 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Paul Wang</investigator_full_name>
    <investigator_title>Professor of Medicine (Cardiovascular Medicine), Stanford University Medical Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

